The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000966392
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
22/06/2026
Date registered
Help: Date registered
6/08/2026
Date last updated
Help: Date last updated
6/08/2026
Date data sharing statement initially provided
Help: Data sharing statement date
6/08/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
DAY-TRIPPER - Feasibility of rapid-access single-fraction stereotactic ablative radiotherapy for cancer patients in regional and rural NSW
Scientific title
DAY-TRIPPER - Feasibility of rapid-access single-fraction stereotactic ablative radiotherapy for cancer patients in regional and rural NSW
Additional trial identifiers [1] 317042 0
Nil
Universal Trial Number (UTN)
Trial acronym
DAY-TRIPPER
Related trial records

Health condition
Health condition(s) studied:
Cancer with lung metastases 341544 0
Cancer recurring in bone 342908 0
Non -small cell lung cancer 342909 0
Condition category
Condition code
Cancer 337615 337615 0 0
Lung - Non small cell
Cancer 337689 337689 0 0
Bone

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
Participants will receive single-fraction stereotactic ablative body radiotherapy (SABR) for either a lung tumour or bone metastasis. Treatment will be delivered according to local departmental protocols, Cancer Institute NSW eviQ recommendations and evidence from published clinical trials.

The intervention will be delivered by a multidisciplinary radiation oncology team comprising a radiation oncologist, radiation therapists and radiation oncology medical physicists. Radiation oncologists will assess eligibility, prescribe the radiation dose, delineate the treatment target and organs at risk, and approve the treatment plan. Radiation therapists will undertake CT simulation, treatment planning, patient positioning, image guidance and treatment delivery. Medical physicists will perform technical review, treatment-plan verification and patient-specific quality assurance. All staff will have relevant clinical training and experience in SABR and image-guided radiotherapy.

The intervention will be delivered to individual participants within the radiation oncology departments at Central Coast Cancer Centre, Calvary Mater Newcastle or North West Cancer Centre, Tamworth.

Participants will undergo a dedicated radiotherapy planning CT scan and an individualised radiotherapy plan will then be developed. Before treatment, the plan will undergo standard clinical review and patient-specific quality assurance. Participants with lung tumours will receive 28–34 Gy in one treatment fraction. Participants with bone metastases will receive 12–24 Gy in one treatment fraction, depending on tumour location, size and clinical considerations. The final prescription will be determined by the treating radiation oncologist.

On the treatment day, participants will be positioned on a linear accelerator treatment couch and undergo cone-beam CT and, where required, additional X-ray imaging to confirm accurate positioning. Further imaging may be performed during or immediately after treatment to assess intrafraction motion and positioning. The radiation treatment itself will be delivered during a single treatment session, compared to a more standard multi-fraction course over several days or weeks.

During Stages 1 and 2, treatment planning and quality-assurance procedures will occur according to each participating department’s usual clinical timeframe. During Stage 3, the same clinical procedures and safety requirements will apply, but the planning and treatment workflow will be streamlined so that CT simulation, planning, quality assurance and treatment are completed within approximately 24 hours. Automation tools may be used to assist contouring, treatment planning and quality assurance; however, all outputs will be reviewed and approved by appropriately qualified clinical staff.

As the intervention consists of a single treatment fraction, there is no multi-session treatment adherence requirement. Attendance and successful treatment delivery will be monitored through the oncology information system, treatment records, image-guidance records and linear accelerator delivery logs. Participants who cannot proceed with single-fraction treatment because of clinical, planning, quality-assurance or positioning concerns will be offered an appropriate standard-of-care radiotherapy regimen at the discretion of the treating radiation oncologist.
Intervention code [1] 333796 0
Treatment: Other
Description of the comparator or control
There is no control group used in this study.
Control group
Uncontrolled

Outcomes
Primary outcome [1] 345113 0
Feasibility of single fraction stereotactic ablative radiotherapy in a regional/rural setting.
Timepoint [1] 345113 0
P1.1 - P1.2 will be collected up to two weeks before the single fraction radiotherapy depending on the clinical category code. P1.3 will be collected one week before before the radiotherapy session. P1.4 will be collected one week after the radiotherapy session.
Secondary outcome [1] 460520 0
Participants experience with single fraction SABR
Timepoint [1] 460520 0
This survey will be sent to the participant one week after the completion of the radiotherapy session.
Secondary outcome [2] 460743 0
Patient travel time with single fraction SABR compared to the standard of care multi-fraction course.
Timepoint [2] 460743 0
This will be collected one month after the radiotherapy session.
Secondary outcome [3] 460744 0
The radiotherapy machine utilisation time for single fraction SABR compared to standard of care multi-fraction courses.
Timepoint [3] 460744 0
This will be collected one month after the radiotherapy treatment session.
Secondary outcome [4] 460745 0
To quantify intra-fraction target motion during during treatment from available imaging on the linear accelerator.
Timepoint [4] 460745 0
This will be calculated and collected one month after the radiotherapy session.
Secondary outcome [5] 460746 0
Calculate the difference between planned and delivered radiation dose to the tumour and surrounding organs at risk (OARs).
Timepoint [5] 460746 0
This will be calculated and collected one month after the radiotherapy treatment session,
Secondary outcome [6] 460747 0
Calculate difference between planned and delivered radiation dose to the tumour due to tumour motion.
Timepoint [6] 460747 0
This will be calculated and collected one month after the radiotherapy session.

Eligibility
Key inclusion criteria
Adults aged greater than or equal to 18 years who can provide written informed consent and complete study surveys, and who are considered suitable for single-fraction SABR by the treating radiation oncologist.

Eligible participants must have either:

A peripheral lung tumour less than or equal to 5cm, comprising stage I–II non-small cell lung cancer or up to three pulmonary metastases from a non-haematological malignancy; or Radiologically confirmed bone metastases,
Eastern Cooperative Oncology Group (ECOG) performance status 0–2,
A life expectancy greater than or equal to 3 months, and pain or dysaesthesia.

Treatment eligibility will follow relevant Cancer Institute NSW eviQ guidelines and published clinical trial criteria.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
Key exclusion criteria are pregnancy, lactation, or being of childbearing potential and unwilling to avoid pregnancy during the study. Patients who are not clinically suitable for single-fraction SABR under the relevant eviQ or protocol criteria will also be excluded.

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Not Applicable
Type of endpoint/s
Statistical methods / analysis
A formal power calculation was not undertaken because this is a feasibility study. The target sample of 40 participants was determined pragmatically from historical caseloads at participating centres, expected eligibility for single-fraction SABR and a conservative recruitment rate of approximately 30%. Thirty participants will be recruited in Stages 1–2, including at least 10 lung and 10 bone cases, with a further 10 participants in Stage 3.

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW
Recruitment hospital [1] 29659 0
Gosford Hospital - Gosford
Recruitment hospital [2] 29660 0
Calvary Mater Newcastle - Waratah
Recruitment hospital [3] 29661 0
North West Cancer Centre - Tamworth Hospital - Tamworth
Recruitment postcode(s) [1] 46006 0
2250 - Gosford
Recruitment postcode(s) [2] 46007 0
2298 - Waratah
Recruitment postcode(s) [3] 46008 0
2340 - Tamworth

Funding & Sponsors
Funding source category [1] 321637 0
Other
Name [1] 321637 0
NSW Regional Health Partners Research Translation Grant
Country [1] 321637 0
Australia
Primary sponsor type
Government body
Name
Central Coast Cancer Centre - Central Coast Local Health District
Address
Country
Australia
Secondary sponsor category [1] 324456 0
None
Name [1] 324456 0
Address [1] 324456 0
Country [1] 324456 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 320159 0
Hunter New England Human Research Ethics Committee
Ethics committee address [1] 320159 0
Ethics committee country [1] 320159 0
Australia
Date submitted for ethics approval [1] 320159 0
27/02/2026
Approval date [1] 320159 0
30/03/2026
Ethics approval number [1] 320159 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 149642 0
Dr Benjamin Zwan
Address 149642 0
Central Coast Cancer Centre- Gosford Hospital - Holden Street Gosford NSW 2250
Country 149642 0
Australia
Phone 149642 0
+612 4320 9868
Fax 149642 0
Email 149642 0
Contact person for public queries
Name 149643 0
Benjamin Zwan
Address 149643 0
Central Coast Cancer Centre- Gosford Hospital - Holden Street Gosford NSW 2250
Country 149643 0
Australia
Phone 149643 0
+612 4320 9868
Fax 149643 0
Email 149643 0
Contact person for scientific queries
Name 149644 0
Benjamin Zwan
Address 149644 0
Central Coast Cancer Centre- Gosford Hospital - Holden Street Gosford NSW 2250
Country 149644 0
Australia
Phone 149644 0
+612 4320 9868
Fax 149644 0
Email 149644 0

Data sharing statement
Will the study consider sharing individual participant data?
No


What supporting documents are/will be available?

TypeCitationLinkEmailOther DetailsAttachment
Ethical approval    2026_ETH00073_ Application HREA - Approved.pdf


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.